Latest Ratios: P/E Ratio -408.9x · EV/EBITDA 24.3x · ROE -0.4%. (1999–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $9.3B | $7.2B | $8.8B | $10.8B | $10.2B | $12.8B | $8.4B | $8.0B | $4.7B | $5.5B | $3.4B |
| Enterprise Value | $11.1B | $8.9B | $10.8B | $11.7B | $10.8B | $13.2B | $8.6B | $8.2B | $4.7B | $5.6B | $3.5B |
| P/E Ratio → | -408.93 | — | 77.13 | 25.34 | 34.35 | 46.36 | 53.07 | 40.45 | 26.11 | 70.04 | 22.29 |
| P/S Ratio | 2.72 | 2.08 | 2.60 | 3.65 | 4.04 | 5.31 | 4.21 | 3.85 | 2.47 | 3.09 | 2.13 |
| P/B Ratio | 3.71 | 2.85 | 4.83 | 7.65 | 9.02 | 11.83 | 8.59 | 8.51 | 5.12 | 7.36 | 4.91 |
| P/FCF | 215.64 | 165.16 | 64.44 | 44.47 | 70.33 | 67.38 | 35.61 | 56.85 | 24.57 | 49.33 | 36.66 |
| P/OCF | 69.63 | 53.33 | 34.87 | 30.89 | 37.21 | 45.43 | 25.19 | 37.40 | 19.52 | 35.36 | 26.26 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.59 | 3.22 | 3.95 | 4.28 | 5.44 | 4.33 | 3.95 | 2.48 | 3.14 | 2.18 |
| EV / EBITDA | 24.29 | 19.49 | 24.78 | 21.22 | 20.78 | 26.18 | 26.16 | 21.74 | 14.36 | 19.92 | 15.14 |
| EV / EBIT | 46.96 | 108.09 | 42.49 | 20.88 | 25.20 | 32.25 | 35.80 | 27.61 | 17.07 | 23.56 | 16.87 |
| EV / FCF | — | 205.44 | 79.60 | 48.14 | 74.63 | 69.09 | 36.59 | 58.29 | 24.66 | 50.14 | 37.40 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 45.9% | 45.9% | 49.0% | 51.0% | 51.6% | 50.0% | 47.3% | 48.0% | 47.5% | 46.0% | 46.1% |
| Operating Margin | 6.9% | 6.9% | 7.5% | 14.7% | 17.1% | 17.1% | 12.5% | 14.5% | 13.8% | 12.2% | 11.0% |
| Net Profit Margin | -0.3% | -0.3% | 3.4% | 14.4% | 11.7% | 11.5% | 7.9% | 9.5% | 9.5% | 4.5% | 9.5% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -0.4% | -0.4% | 7.0% | 33.6% | 26.8% | 26.9% | 16.5% | 21.3% | 21.7% | 10.9% | 21.3% |
| ROA | -0.1% | -0.1% | 2.2% | 10.9% | 8.2% | 8.3% | 5.4% | 8.0% | 8.8% | 4.2% | 8.7% |
| ROIC | 4.4% | 4.4% | 6.1% | 16.1% | 20.5% | 23.7% | 15.9% | 21.8% | 22.3% | 20.1% | 17.6% |
| ROCE | 5.0% | 5.0% | 6.7% | 15.2% | 16.0% | 16.6% | 11.3% | 16.5% | 17.8% | 15.8% | 14.4% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.81 | 0.81 | 1.24 | 0.98 | 1.12 | 1.28 | 0.94 | 0.94 | 0.37 | 0.56 | 0.59 |
| Debt / EBITDA | 4.48 | 4.48 | 5.14 | 2.50 | 2.44 | 2.77 | 2.78 | 2.34 | 1.04 | 1.49 | 1.78 |
| Net Debt / Equity | — | 0.69 | 1.14 | 0.63 | 0.55 | 0.30 | 0.24 | 0.22 | 0.02 | 0.12 | 0.10 |
| Net Debt / EBITDA | 3.82 | 3.82 | 4.72 | 1.62 | 1.20 | 0.65 | 0.70 | 0.54 | 0.06 | 0.33 | 0.30 |
| Debt / FCF | — | 40.28 | 15.16 | 3.66 | 4.30 | 1.71 | 0.98 | 1.44 | 0.10 | 0.82 | 0.74 |
| Interest Coverage | 1.36 | 1.36 | 5.32 | 34.18 | 26.71 | 28.52 | 16.68 | 18.52 | 21.84 | 15.30 | 15.74 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.73 | 1.73 | 1.60 | 1.80 | 2.31 | 2.63 | 2.43 | 2.78 | 2.18 | 2.59 | 2.42 |
| Quick Ratio | 0.87 | 0.87 | 0.77 | 0.99 | 1.44 | 1.88 | 1.56 | 1.89 | 1.33 | 1.66 | 1.58 |
| Cash Ratio | 0.23 | 0.23 | 0.14 | 0.41 | 0.71 | 1.24 | 0.92 | 1.06 | 0.54 | 0.84 | 0.95 |
| Asset Turnover | — | 0.55 | 0.58 | 0.70 | 0.70 | 0.66 | 0.65 | 0.75 | 0.89 | 0.91 | 0.89 |
| Inventory Turnover | 1.70 | 1.70 | 1.61 | 1.50 | 1.53 | 1.70 | 1.51 | 1.87 | 1.95 | 1.96 | 1.97 |
| Days Sales Outstanding | — | 78.17 | 76.03 | 76.56 | 85.86 | 62.93 | 61.58 | 63.79 | 68.78 | 66.00 | 55.25 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 0.2% | 0.3% | 0.3% | 0.3% | 0.3% | 0.2% | 0.3% | 0.3% | 0.5% | 0.5% | 0.8% |
| Payout Ratio | — | — | 26.7% | 6.9% | 10.0% | 8.7% | 15.6% | 12.7% | 14.0% | 32.3% | 16.8% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 1.3% | 3.9% | 2.9% | 2.2% | 1.9% | 2.5% | 3.8% | 1.4% | 4.5% |
| FCF Yield | 0.5% | 0.6% | 1.6% | 2.2% | 1.4% | 1.5% | 2.8% | 1.8% | 4.1% | 2.0% | 2.7% |
| Buyback Yield | 0.1% | 0.1% | 0.0% | 1.4% | 2.6% | 1.2% | 1.5% | 1.8% | 0.0% | 2.8% | 4.7% |
| Total Shareholder Yield | 0.4% | 0.5% | 0.3% | 1.7% | 2.9% | 1.4% | 1.8% | 2.1% | 0.5% | 3.3% | 5.4% |
| Shares Outstanding | — | $152M | $150M | $147M | $149M | $153M | $155M | $157M | $157M | $159M | $162M |
Acquisition-driven margin dilution
Based on current market data, Bruker's forward P/E of 28.75 suggests investors are pricing in significant execution risk, as the valuation remains compressed relative to peers like Waters Corporation, which trades at a higher multiple despite similar exposure to cyclical life science capital expenditure cycles.
The negative TTM P/E ratio highlights the impact of recent acquisition-related charges on bottom-line earnings, making traditional valuation metrics less reliable for assessing intrinsic value. Investors should monitor whether the forward multiple accurately captures the potential for margin recovery as the company integrates its recent clinical diagnostic assets.
As reported in financial statements, Bruker's operating margin has contracted to 1.2% in 2026Q1, a sharp decline from the 12.1% observed in 2023Q4, indicating that the company's high fixed-cost structure is currently struggling to absorb the costs associated with its recent aggressive inorganic expansion strategy.
While gross margins remain relatively resilient at 46.1%, the collapse in operating profitability suggests that R&D and SG&A expenses are outpacing revenue growth. This trend warrants further investigation into whether these costs are temporary integration hurdles or a structural shift toward lower-margin clinical diagnostic markets.
According to recent quarterly filings, Bruker's ROIC has plummeted to 0.2% in 2026Q1 from 3.5% in 2023Q4, signaling that the company is currently failing to generate adequate returns on its invested capital as it pivots toward new, less familiar segments like spatial biology and clinical diagnostics.
The significant decay in return metrics suggests that the capital deployed for recent acquisitions is not yet contributing to operational efficiency. This decline appears to be driven by both the dilution of the capital base and the immediate pressure of integration costs on net income.
Based on the provided data, Bruker's cash conversion cycle has expanded to 245 days in 2026Q1, reflecting persistent inefficiencies in inventory management and the long lead times inherent in the company's high-end instrument manufacturing and installation processes compared to its historical performance.
The elevated DIO of 225 days suggests that the company is carrying significant inventory, which may be a strategic buffer for supply chain stability but ultimately ties up critical liquidity. Investors should monitor whether these cycle times improve as the company attempts to streamline its operations post-acquisition.
The P/E ratio is frequently misapplied to Bruker's business model, as it fails to account for the lumpy, project-based revenue recognition of the BEST segment and the significant non-cash amortization charges resulting from the company's recent aggressive acquisition strategy in the clinical diagnostics space.
Analysts should instead focus on EV/EBITDA or free cash flow yield to better understand the underlying cash-generating capacity of the core scientific instruments business. Relying on P/E ratios in the current environment likely obscures the company's true operational health by focusing on accounting earnings that are heavily distorted by one-time integration costs.
Includes 30+ ratios · 27 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BRKR stock.
Bruker Corporation's current P/E ratio is -408.9x. The historical average is 38.5x.
Bruker Corporation's current EV/EBITDA is 24.3x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 25.0x.
Bruker Corporation's return on equity (ROE) is -0.4%. The historical average is 12.3%.
Based on historical data, Bruker Corporation is trading at a P/E of -408.9x. Compare with industry peers and growth rates for a complete picture.
Bruker Corporation's current dividend yield is 0.24%.
Bruker Corporation has 45.9% gross margin and 6.9% operating margin.
Bruker Corporation's Debt/EBITDA ratio is 4.5x, indicating high leverage. A ratio above 4x may signal elevated financial risk.